Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
United Therapeutic
(NQ:
UTHR
)
348.03
+1.16 (+0.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about United Therapeutic
< Previous
1
2
3
4
5
6
Next >
Short Volatility Alert: United Therapeutics Corporation
May 26, 2022
On Wednesday, shares of United Therapeutics Corporation (NASDAQ: UTHR) experienced volatile short activity. After the activity, the stock price went up 4.31% to $228.39. The...
Via
Benzinga
United Therapeutics Stock Sees RS Rating Jump To 89; Earns 'Blue Dot'
May 24, 2022
United Therapeutics stock had its Relative Strength (RS) Rating upgraded to 89 Tuesday, from 71 a day earlier.
Via
Investor's Business Daily
Expert Ratings for United Therapeutics
May 24, 2022
Within the last quarter, United Therapeutics (NASDAQ:UTHR) has observed the following analyst ratings:
Via
Benzinga
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
May 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
United Therapeutics's Return on Invested Capital Insights
May 18, 2022
According to Benzinga Pro, during Q1, United Therapeutics (NASDAQ:UTHR) earned $239.90 million, a 113.81% increase from the preceding quarter. United Therapeutics also posted a total of $461.90 million...
Via
Benzinga
7 Biotech Stocks With Key Catalysts for May
May 11, 2022
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns.
Via
InvestorPlace
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Recap: United Therapeutics Q1 Earnings
May 04, 2022
United Therapeutics (NASDAQ:UTHR) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For May 4, 2022
May 04, 2022
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Via
Benzinga
Earnings Outlook For United Therapeutics
May 03, 2022
United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that United...
Via
Benzinga
United Therapeutics Q1 2022 Earnings Conference Call On May 4, 2022 At 09:00 AM ET
April 29, 2022
United Therapeutics (NASDAQ:UTHR) will host a conference call at 09:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to Attend United Therapeutics (UTHR) Conference Call Follow this...
Via
Benzinga
First Human With Pig Heart Transplant Dies: Reuters
March 09, 2022
A 57-year-old man with terminal heart disease who became the first person to receive a genetically modified pig's heart has died, the University of Maryland Medical...
Via
Benzinga
10 Biggest Price Target Changes For Monday
February 28, 2022
Barclays cut the price target on MasTec, Inc. (NYSE: MTZ) from $140 to $120. MasTec shares fell 0.1% to $79.00 in pre-market trading.
Via
Benzinga
United Therapeutics Earnings Perspective: Return On Capital Employed
February 25, 2022
Pulled from Benzinga Pro data, United Therapeutics (NASDAQ:UTHR) posted Q4 earnings of $112.20 million, an increase from Q3 of 31.04%. Sales dropped to $415.20 million, a 6.63%...
Via
Benzinga
FDA Pushes United Therapeutics-MannKind Tyvaso DPI's Decision Date; United Therapeutics' Q4 Misses Consensus
February 24, 2022
United Therapeutics Corp (NASDAQ: UTHR) and its partner MannKind Corp (NASDAQ: MNKD) have received an FDA information request letter for additional...
Via
Benzinga
United Therapeutics's Earnings Outlook
February 23, 2022
United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
First Successful Pig Heart Transplant Into Human: Details On The Amazing Technology And A Public Company To Watch
January 11, 2022
Pigs may not be able to fly, but they've provided a vital organ in a life-saving surgery for one U.S. man. What Happened: A Maryland hospital completed the first...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 11, 2022
Gainers Black Diamond Therapeutic (NASDAQ:BDTX) stock increased by 18.2% to $5.32 during Tuesday's pre-market session. The market value of their outstanding shares is...
Via
Benzinga
7 Pharmaceutical Stocks That Could Make You Rich
January 06, 2022
Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich
Via
InvestorPlace
Mark To Market
January 02, 2022
I thought that I would have a look at my own financial performance in 2021. In preview, I did alright, but not as well as the market. Let's take a look at what my portfolio held and how well it did.
Via
Talk Markets
Liquidia's Inhaled Treprostinil Powder Scores Tentative FDA Approval For PAH
November 08, 2021
The FDA has granted tentative approval to Liquidia Corporation's (NASDAQ: LQDA) Yutrepia (treprostinil) inhalation powder for pulmonary arterial...
Via
Benzinga
Exposures
Product Safety
United Therapeutics Corporation (UTHR) Q3 2021 Earnings Call Transcript
November 03, 2021
UTHR earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
November 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...
Via
Benzinga
Topics
Retirement
Exposures
Pension
Recap: United Therapeutics Q3 Earnings
November 03, 2021
United Therapeutics (NASDAQ:UTHR) reported its Q3 earnings results on Wednesday, November 3, 2021 at 08:00 AM. Here's what investors need to know about the announcement...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
November 02, 2021
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a...
Via
Benzinga
Why Shares of MannKind Corporation Are Falling This Morning
October 18, 2021
Investors are hyperventilating after a delay for its inhaled medicine.
Via
The Motley Fool
FDA Declines MannKind - United Therapeutics' Formulated Treprostinil For Lung Disease
October 18, 2021
The FDA has issued a complete response to United Therapeutics Corporation (NASDAQ: UTHR) regarding the marketing application for Tyvaso DPI for pulmonary...
Via
Benzinga
Exposures
Product Safety
Earnings Scheduled For November 3, 2021
November 03, 2021
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion....
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
October 01, 2021
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.